RBC Capital raised the firm’s price target on to $125 from $110 and keeps an Outperform rating on the shares. The company posted a strong start to 2025 with first quarter results well ahead of expectations and a commensurate guidance raise, the analyst tells investors in a research note. Encompass Health (EHC) saw a notable shift in payer mix with Medicare FFS volume outpacing MA for the first time since 2022, RBC adds.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EHC:
- Encompass Health price target raised to $130 from $120 at Raymond James
- Encompass Health price target raised to $130 from $110 at Mizuho
- Encompass Health: Strong Performance and Strategic Expansion Drive Buy Rating
- Encompass Health’s Strong Q1 2025 Performance and Strategic Moves Justify Buy Rating
- Encompass Health Stock (EHC) Surges Following Strong Q1 Results and Strategic Expansion Plans